The mechanistic role of DNA methylation in myeloid leukemogenesis

Leukemia

Volumn 28, Issue 9, 2014, Pages 1765-1773

  Jasielec, J ^a   Saloura, V ^a   Godley, L A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYTOSINE; DECITABINE; DNA BASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; METHYL CPG BINDING PROTEIN 1; METHYL CPG BINDING PROTEIN 2; METHYL CPG BINDING PROTEIN 3; METHYL CPG BINDING PROTEIN 4; THYMINE DNA GLYCOSYLASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; BONE MARROW; CANCER PROGNOSIS; CELL PROLIFERATION; COVALENT BOND; CPG ISLAND; DEMETHYLATION; DNA DAMAGE; DNA METHYLATION; DNA REPLICATION; DRUG BLOOD LEVEL; EPIGENETICS; GENE MUTATION; HISTONE CODE; HUMAN; HUMAN CELL; HUMAN GENOME; LEUKEMIA REMISSION; LEUKEMOGENESIS; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; REVIEW; SPONTANEOUS MUTATION; TISSUE DIFFERENTIATION;

AZACITIDINE; CLINICAL TRIALS AS TOPIC; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; HUMANS; LEUKEMIA, MYELOID; MUTATION;

EID: 84908280724     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.163     Document Type: Review

References (84)

1. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet. 2013; 14: 765-780
2. Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. Nature. 2013; 502: 480-488
3. Lakshmikuttyamma A, Scott SA, DeCoteau JF, Geyer CR. Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene. 2010; 29: 576-588
4. Neff T, Armstrong SA. Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood. 2013; 121: 4847-4853
5. Ehrlich M, Gama-Sosa MA, Huang LH, Midgett RM, Kuo KC, McCune RA., et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res. 1982; 10: 2709-2721
6. Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer. 2013; 13: 497-510
7. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983; 301: 89-92
8. Estecio MR, Issa JP. Dissecting DNA hypermethylation in cancer. FEBS Lett. 2011; 585: 2078-2086
9. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P., et al. The human colon cancer methylome shows similar hypo- And hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009; 41: 178-186
10. Cokus SJ, Feng S, Zhang X, Chen Z, Merriman B, Haudenschild CD., et al. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature. 2008; 452: 215-219
11. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009; 462: 315-322
12. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002; 16: 6-21
13. Wyatt MD. Advances in understanding the coupling of DNA base modifying enzymes to processes involving base excision repair. Adv Cancer Res. 2013; 119: 63-106
14. Teperek-Tkacz M, Pasque V, Gentsch G, Ferguson-Smith AC. Epigenetic reprogramming: is deamination key to active DNA demethylation? Reproduction. 2011; 142: 621-632
15. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J., et al. Initial sequencing and analysis of the human genome. Nature. 2001; 409: 860-921
16. Franchini DM, Schmitz KM, Petersen-Mahrt SK. 5-Methylcytosine DNA demethylation: more than losing a methyl group. Annu Rev Genet. 2012; 46: 419-441
17. Branco MR, Ficz G, Reik W. Uncovering the role of 5-hydroxymethylcytosine in the epigenome. Nat Rev Genet. 2012; 13: 7-13
18. Madzo J, Liu H, Rodriguez A, Vasanthakumar A, Sundaravel S, Caces DB., et al. Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Rep. 2014; 6: 231-244
19. Mariani CJ, Madzo J, Moen EL, Yesilkanal A, Godley LA. Alterations of 5-hydroxymethylcytosine in human cancers. Cancers (Basel) 2013; 5: 786-814
20. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D., et al. Many human large intergenic noncoding RNAs associate with chromatinmodifying complexes and affect gene expression. Proc Natl Acad Sci USA. 2009; 106: 11667-11672
21. Schmitz KM, Mayer C, Postepska A, Grummt I. Interaction of noncoding RNA with the rDNA promoter mediates recruitment of DNMT3b and silencing of rRNA genes. Genes Dev. 2010; 24: 2264-2269
22. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E., et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009; 113: 6411-6418
23. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S., et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010; 107: 7473-7478
24. Froberg JE, Yang L, Lee JT. Guided by RNAs: X-inactivation as a model for lncRNA function. J Mol Biol. 2013; 425: 3698-3706
25. Yildirim E, Kirby JE, Brown DE, Mercier FE, Sadreyev RI, Scadden DT., et al. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell. 2013; 152: 727-742
26. Li D, Feng J, Wu T, Wang Y, Sun Y, Ren J., et al. Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. Am J Pathol. 2013; 182: 64-70
27. Lu L, Zhu G, Zhang C, Deng Q, Katsaros D, Mayne ST., et al. Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer. Breast Cancer Res Treat. 2012; 136: 875-883
28. Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR., et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med. 2013; 210: 2641-2659
29. Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL., et al. Array-based genomic resequencing of human leukemia. Oncogene. 2010; 29: 3723-3731
30. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363: 2424-2433
31. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y., et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011; 43: 309-315
32. Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood. 2013; 122: 4086-4089
33. Pawlak M, Jaenisch R. De novo DNA methylation by Dnmt3a and Dnmt3b is dispensable for nuclear reprogramming of somatic cells to a pluripotent state. Genes Dev. 2011; 25: 1035-1040
34. Green CL, Evans CM, Hills RK, Burnett AK, Linch DC, Gale RE. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood. 2010; 116: 2779-2782
35. Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC., et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 2011; 118: 409-412
36. Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ., et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011; 118: 5593-5603
37. Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H., et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011; 29: 1373-1381
38. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366: 1079-1089
39. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18: 553-567
40. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS., et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2012; 44: 23-31
41. Jeong M, Sun D, Luo M, Huang Y, Challen GA, Rodriguez B., et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat Genet. 2014; 46: 17-23
42. Yu M, Hon GC, Szulwach KE, Song CX, Jin P, Ren B., et al. Tet-Assisted bisulfite sequencing of 5-hydroxymethylcytosine. Nat Protoc. 2012; 7: 2159-2170
43. Yu M, Hon GC, Szulwach KE, Song CX, Zhang L, Kim A., et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell. 2012; 149: 1368-1380
44. Booth MJ, Branco MR, Ficz G, Oxley D, Krueger F, Reik W., et al. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science. 2012; 336: 934-937
45. Booth MJ, Ost TW, Beraldi D, Bell NM, Branco MR, Reik W., et al. Oxidative bisulfite sequencing of 5-methylcytosine and 5-hydroxymethylcytosine. Nat Protoc. 2013; 8: 1841-1851
46. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10: 223-232
47. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20: 2429-2440
48. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106: 1794-1803
49. Gurion R, Vidal L, Gafter-Gvili A, Belnik Y, Yeshurun M, Raanani P., et al. 5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome-A systematic review and meta-Analysis. Haematologica. 2010; 95: 303-310
50. Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER., et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer. 2005; 93: 1388-1394
51. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z., et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 2004; 64: 4294-4301
52. Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A., et al. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-Azacytidine or decitabine therapy. Clin Cancer Res. 2013; 19: 938-948
53. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980; 20: 85-93
54. Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-Azacytidine on L1210 leukemia. Cancer Res. 1970; 30: 2760-2769
55. Flatau E, Gonzales FA, Michalowsky LA, Jones PA. DNA methylation in 5-Aza-2'-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells. Mol Cell Biol. 1984; 4: 2098-2102
56. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-Azacytosine. Proc Natl Acad Sci USA. 1984; 81: 6993-6997
57. Datta J, Ghoshal K, Motiwala T, Jacob ST. Novel insights into the molecular mechanism of action of DNA hypomethylating agents: role of protein kinase C delta in decitabine-induced degradation of DNA methyltransferase 1. Genes Cancer. 2012; 3: 71-81
58. Taylor SM, Jones PA. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-Azacytidine. Cell. 1979; 17: 771-779
59. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V., et al. DNA methylation changes after 5-Aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006; 66: 5495-5503
60. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood. 2002; 100: 2957-2964
61. Stresemann C, Bokelmann I, Mahlknecht U, Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther. 2008; 7: 2998-3005
62. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. J Int Cancer. 2008; 123: 8-13
63. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH., et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-Azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009; 114: 2764-2773
64. Claus R, Pfeifer D, Almstedt M, Zucknick M, Hackanson B, Plass C., et al. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. Leukemia Res. 2013; 37: 190-196
65. Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V., et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood. 2013; 121: 1633-1643
66. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood. 2008; 111: 2382-2384
67. Suzuki H, Maruyama R, Yamamoto E, Kai M. DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 2012; 6: 567-578
68. Baer C, Claus R, Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res. 2013; 73: 473-477
69. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N., et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One. 2010; 5: e9001
70. Lu LW, Chiang GH, Medina D, Randerath K. Drug effects on nucleic acid modification. I. A specific effect of 5-Azacytidine on mammalian transfer RNA methylation in vivo. Biochem Biophys Res Commun. 1976; 68: 1094-1101
71. Lu LJ, Randerath K. Effects of 5-Azacytidine on transfer RNA methyltransferases. Cancer Res. 1979; 39: 940-949
72. Schaefer M, Hagemann S, Hanna K, Lyko F. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res. 2009; 69: 8127-8132
73. Xu J, Wang YY, Dai YJ, Zhang W, Zhang WN, Xiong SM., et al. DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proc Natl Acad Sci USA. 2014; 111: 2620-2625
74. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011; 20: 11-24
75. Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O., et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011; 20: 25-38
76. Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R., et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA. 2011; 108: 14566-14571
77. Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE., et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011; 118: 4509-4518
78. Shide K, Kameda T, Shimoda H, Yamaji T, Abe H, Kamiunten A., et al. TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia. 2012; 26: 2216-2223
79. Dawlaty MM, Breiling A, Le T, Raddatz G, Barrasa MI, Cheng AW., et al. Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev Cell. 2013; 24: 310-323
80. Muto T, Sashida G, Oshima M, Wendt GR, Mochizuki-Kashio M, Nagata Y., et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med. 2013; 210: 2627-2639
81. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A., et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 2012; 488: 656-659
82. Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Yun H, Gorlich K., et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood. 2013; 122: 2877-2887
83. Chen C, Liu Y, Lu C, Cross JR, JPt Morris, Shroff AS., et al. Cancer-Associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev. 2013; 27: 1974-1985
84. Mylonas E, Janin M, Bawa O, Opolon P, David M, Quivoron C., et al. Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice. Leukemia. 2014; 28: 1343-1346